Survey of leading theranostic centers: most are meeting ¹⁷⁷Lu-PSMA demand today, but flag staffing, capacity, and imaging as volumes grow. The next challenge isn't innovation — it's implementation. hubs.ly/Q04s5mMH0

Better targets make better theranostics. New review: CAIX-targeted radiopharmaceuticals in clear cell RCC — tumor specificity that supports a real see-and-treat approach. hubs.ly/Q04s5lxj0 #Theranostics

New review — a four-step framework for ²¹²Pb alpha therapy: patient selection, personalized dosimetry, safety monitoring, registry science. hubs.ly/Q04s5kyx0 #TAT

First-in-human: ¹⁶¹Tb-FAPI-2286 in metastatic papillary thyroid cancer. Successful labeling, favorable biodistribution, dosimetry, and early safety. hubs.ly/Q04s5mgQ0

Head-to-head in 140 matched mCRPC patients: commercial ¹⁷⁷Lu-PSMA-617 vs in-house ¹⁷⁷Lu-PSMA I&T. Deeper PSA responses with 617 (70% vs 54%). Comparable overall survival. In-house held its own. hubs.ly/Q04s5n570

¹⁶¹Tb isn't just killing tumor cells — it's priming the immune system. Dual-target S1R/PSMA peptide + ¹⁶¹Tb: 60% complete regression at 7.4 MBq. At 3.7 MBq it sensitized "cold" tumors to anti-PD1 — 50% cure rate. hubs.ly/Q04s5lmK0

Earlier isn't automatically better for ¹⁷⁷Lu-PSMA-617. VISION > PSMAfore > PSMAddition. New Viewpoint from Dr. Arif Hakan Önder: PSMA presence ≠ PSMA readiness. Sequence RPT by tumor biology, not the calendar. hubs.ly/Q04s5kWX0 #Theranostics #PSMA

For an emerging isotope, the hard part isn't the target — it's reliable production. Tata Memorial Centre (ACTREC) validated an in-house Tb-161 DOTATATE protocol: >99% radiochemical yield and purity, stable in serum for 7 days. hubs.ly/Q04r_KYT0 #Theranostics

Cu-64 images. Cu-67 treats. Same DOTA platform, same targeting molecule. New study: a clinic-ready automated synthesis of Cu-64 FAPI-2286, plus a first look at FAP imaging in liver fibrosis. hubs.ly/Q04r_ycL0 #Theranostics #Copper64

αvβ6 delivers the radiation. PARP inhibition stops the repair. UC Davis researchers paired a Lu-177 radioligand with olaparib in pancreatic cancer models: more DNA double-strand breaks, delayed tumor growth, longer survival. hubs.ly/Q04r_TmZ0 #Theranostics

Which mCRPC patients will actually respond to radium-223? A new Journal of Nuclear Medicine study suggests a ctDNA blood test may help answer that — before treatment starts. hubs.ly/Q04r_pBG0

MD → FDA Commissioner → CEO. Few people have seen drug development from as many angles as Steve Hahn, MD. In a new GeneOnline interview, our CEO explains why breakthrough science is only the starting point. hubs.ly/Q04s4KTK0 #Radiopharmaceuticals #Leadership

New research in the Journal for ImmunoTherapy of Cancer describes a CD70-targeted theranostic for multiple myeloma—pairing immunoPET imaging with RPT. Preclinical models showed precise imaging, antitumor activity & a favorable safety profile. 🔗 hubs.ly/Q04rYLfD0 #RPT

The future of theranostics may be defined by a portfolio of radiometals matched to different targets and strategies. A new review explores emerging roles for ¹⁴⁹Tb, ⁴⁴Sc, ⁵²Mn, ²⁰³Pb, and ⁵⁵Co. 🔗 hubs.ly/Q04nXChy0 #Theranostics

New review in Clinical & Translational Imaging on tumor dosimetry in radioligand therapy—making the case for standardized protocols & individualized treatment planning as RPT scales clinically. #Radiopharma #Theranostics #Dosimetry 🔗hubs.ly/Q04n34yL0

Glioblastoma is one of the hardest cancers to diagnose and treat. A new JNM study evaluates FAPI-46 as a theranostic platform—pairing PET imaging with targeted radionuclide therapy. 🔗 hubs.ly/Q04nXvVR0 #PRT #Theranostics

PRRT transformed treatment for GEP-NETs. A new review charts what's next: alpha-emitting radiopharmaceuticals, novel targeting strategies, and greater personalization—expanding options, not replacing standards of care. 🔗 hubs.ly/Q04nXBmm0 #Radiopharma #PRRT

New preclinical study: [177Lu]Lu-AKIR001, a CD44v6-targeted radiopharmaceutical, drove activity-dependent tumor inhibition in pancreatic cancer models—complete remissions in monotherapy & a low-dose paclitaxel combo. #Radiopharma #Theranostics 🔗 hubs.ly/Q04pwk1C0

Mayo Clinic + GE HealthCare launch MI-BET: can imaging & biomarkers adapt radioligand therapy to each patient — not a preset cycle count? Congrats to PI Matthew Thorpe, MD, PhD & our own CSO Geoff Johnson, MD, PhD (Co-PI). Adaptive RLT is the future we're building for. 🔗 Link

Targeted alpha therapies keep gaining momentum. A new review explores how nanocarriers could sharpen tumor targeting, spare healthy tissue & optimize radionuclide delivery—pointing to next-gen theranostics. 🔗 hubs.ly/Q04nPZGL0 #Radiopharma #Theranostics